Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a p… Read more
Inhibikase Therapeutics Inc (IKT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.145x
Based on the latest financial reports, Inhibikase Therapeutics Inc (IKT) has a cash flow conversion efficiency ratio of -0.145x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.59 Million) by net assets ($72.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Inhibikase Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Inhibikase Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Inhibikase Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inhibikase Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Titanium Transportation Group Inc.
TO:TTNM
|
0.119x |
|
Precise Corporation Public Company Limited
BK:PCC
|
0.076x |
|
NEBAG NA SF 0,02
F:NWR
|
N/A |
|
Humasis Co. Ltd
KQ:205470
|
0.036x |
|
351
F:351
|
0.400x |
|
Soundwill Holdings Limited
PINK:SDWHF
|
0.006x |
|
Eurasia Mining Plc
F:EUH
|
-0.017x |
|
Security Federal Corporation
PINK:SFDL
|
0.031x |
Annual Cash Flow Conversion Efficiency for Inhibikase Therapeutics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Inhibikase Therapeutics Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $94.87 Million | $-19.15 Million | -0.202x | +87.75% |
| 2023-12-31 | $10.98 Million | $-18.09 Million | -1.647x | -99.72% |
| 2022-12-31 | $21.04 Million | $-17.35 Million | -0.825x | -121.63% |
| 2021-12-31 | $38.42 Million | $-14.30 Million | -0.372x | -222.43% |
| 2020-12-31 | $9.78 Million | $-1.13 Million | -0.115x | -253.20% |
| 2019-12-31 | $-4.49 Million | $-338.29K | 0.075x | +108.20% |
| 2018-12-31 | $-777.97K | $714.99K | -0.919x | -1147.82% |
| 2017-12-31 | $-1.44 Million | $-126.39K | 0.088x | +300.90% |
| 2016-12-31 | $-1.35 Million | $-29.57K | 0.022x | -- |